Non-compliance to mass drug administration associated with the low perception of the community members about their susceptibility to lymphatic filariasis in Ankobra, Ghana

(E-pub Ahead of Print)

Author(s): Ilo Dicko*, Yaya Ibrahim Coulibaly, Modibo Sangaré, Bismark Sarfo, Priscillia Awo Nortey.

Journal Name: Infectious Disorders - Drug Targets

Become EABM
Become Reviewer


Background: Lymphatic filariasis (LF) is a parasitic disease that has been targeted for elimination through the Mass Drug Administration (MDA.) Although the MDA started in the Ankobra community in Ghana in 2000, LF prevalence as reported in 2014 was relatively high (4.5%). Non-compliance to the MDA has been associated with the persistent LF prevalence in endemic regions.

Objective: This study determined the factors associated with the non-compliance to the MDA among patients living in the Ankobra community, Ghana.

Methods: A cross-sectional study using a one-stage cluster sampling method was used to collect data between June and July, 2017 in Ankobra. Questionnaires were used to collect data from health workers, the MDA drug distributors and study participants in Ankobra. Data analysis was performed using STATA 14. Logistic regression was used to measure the degree of association between the dependent (non-compliance) and independent variables. Non-compliance rate was defined as the percentage of individuals who self-reported that they did not actually swallow the drugs provided during the MDA.

Results: The MDA coverage and non-compliance rates were 73.5% (147/200) and 33.33% (49/147) respectively. The main reason for non-compliance was fear of drug adverse events (75.51%, 37/49). Thought of “not being susceptible to LF” was significantly associated with the non-compliance (aOR= 2.83, [CI= 1.15, 6.98]).

Conclusion: Health education about the susceptibility of residents getting LF disease in endemic community must be intensified to improve compliance to MDA medication ingestion and thus meet the Global Elimination of Lymphatic Filariasis by 2020.

Keywords: lymphatic filariasis, mass drug administration, non-compliance, Ankobra

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1871526519666190206210808
Price: $95